Project description DEENESFRITPL A new diagnostic tool will help physicians find and treat arrhythmia in a heartbeat Every day, the heart expands and contracts about 100 000 times, pumping approximately 7 500 litres of blood annually. Rhythmic contraction is induced by electrical activity of the so-called pacemaker, a group of cells in the cardiac wall, and is important for adequate oxygenation of all the body’s tissues. Atrial fibrillation is a loss of rhythm when the heart’s pacemakers start firing in a disorganised way. It is a major cause of stroke that is treated with ablation of the abnormal tissue where the spurious signals arise. CathVision Cube is developing a pioneering electrophysiological recording system with AI-assisted guidance to help in identifying and ablating the source of atrial fibrillation with important impacts on the healthcare sector and affected individuals. Show the project objective Hide the project objective Objective Cardiac arrhythmias are projected to rise during next years. The most prevalent type, Atrial Fibrillation, is projected to increase in the EU from 8.8m in 2010 to 17.9m by the year 2060, leading to a strain on physicians and health systems. Thus, better ablation guiding tools will be necessary to help physicians more efficiently identify, characterise and treat arrhythmias, facilitating training of new electrophysiologists, while reducing procedure and medicine costs. Sex-specific CVD also needs to be better addressed, as it is currently often misdiagnosed in females due to smaller cardiac signals and standards based on male physiology.CathVision Cube is a low-noise electrophysiology (EP) recording system that combines a cutting-edge amplifier with AI assisted decision-making and easy-to-use user interface. Physicians will have access to exceptional EP signals thanks to proprietary hardware technology that reduces noise, prevents signal artefacts and improves signal quality. Doctors will also gain electrogram-driven clinical decision support through the intuitive and logical graphical interface of our AI-software, which allows proper identification of arrhythmogenic areas and guidance to a successful ablation – particularly important for less experienced EP physicians. Moreover, our system enables data export to Electronic Medical Records (EMR), integrates seamlessly into the hospital environment and is also compatible with third-party equipment.Our goal is to mature, pilot and commercialise our CathVision Cube – the world first low-noise EP recording system and AI-assisted decision-making for physicians performing cardiac ablation therapy. A successful CathVision Cube project will create measurable impacts on our company, quantified as accumulated revenue of €457m in 5 years (2021-2025), accumulated operating profit of €348m, creating 45 FTE in our value chain, generating €1.35m in reduced annual costs per hospital and unlocking public savings of €1.1bn by 2025 Fields of science medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmiamedical and health sciencesbasic medicinephysiology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME - SME instrument Coordinator CATHVISION APS Net EU contribution € 2 175 621,00 Address Titangade 11 2200 Kobenhavn Denmark See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Byen København Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 993 660,25
